Sri Yadadri Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 8.00 Cr
as on 26-06-2024
- Paid Up Capital ₹ 7.50 Cr
as on 26-06-2024
- Company Age 18 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Satisfied Charges ₹ 18.08 Cr
as on 26-06-2024
- Revenue 1.14%
(FY 2021)
- Profit 93.64%
(FY 2021)
- Ebitda -75.98%
(FY 2021)
- Net Worth 41.99%
(FY 2021)
- Total Assets -7.05%
(FY 2021)
About Sri Yadadri Lifesciences
The Corporate was formerly known as Pravah Laboratories Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 8.00 Cr and a paid-up capital of Rs 7.50 Cr.
The company has closed loans amounting to ₹18.08 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Moku Reddy and Vasudeva Madabhooshini serve as directors at the Company.
- CIN/LLPIN
U24239TG2006PTC049566
- Company No.
049566
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Mar 2006
- Date of AGM
31 Dec 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Sri Yadadri Lifesciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vasudeva Madabhooshini  | Managing Director | 22-Mar-2006 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Moku Reddy | Director | 04-Jun-2007 | Current |
Financial Performance and Corporate Structure Insights of Sri Yadadri Lifesciences.
Sri Yadadri Lifesciences Private Limited, for the financial year ended 2021, experienced modest growth in revenue, with a 1.14% increase. The company also saw a substantial improvement in profitability, with a 93.64% increase in profit. The company's net worth Soared by an impressive increase of 41.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sri Yadadri Lifesciences?
In 2021, Sri Yadadri Lifesciences had a promoter holding of 12.99% and a public holding of 87.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 11 Jun 2010 | ₹10.13 Cr | Satisfied |
Syndicate Bank Creation Date: 07 Nov 2009 | ₹5.00 M | Satisfied |
Syndicate Bank Creation Date: 29 Mar 2007 | ₹1.50 Cr | Satisfied |
How Many Employees Work at Sri Yadadri Lifesciences?
Sri Yadadri Lifesciences has a workforce of 20 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Jul 27, 2020, Sri Yadadri Lifesciences has raised a total of ₹ 4.19 Cr, with the most recent deal valued at ₹ 1.3 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
